Literature DB >> 25711313

Prevalence and significance of two major inherited thrombophilias in infective endocarditis.

Emanuele Durante-Mangoni1, Domenico Iossa, Rosa Molaro, Roberto Andini, Irene Mattucci, Umberto Malgeri, Rosina Albisinni, Riccardo Utili.   

Abstract

The pathogenesis of infective endocarditis (IE) involves activation of the haemostasis system at the site of endocardial defects. Whether prothrombotic conditions are associated with IE by enhancing early vegetation formation is unknown. In this study, we assess the prevalence and clinical significance of two major conditions associated with thrombophilia in patients with IE. Mutations G20210A of the prothrombin (PTH) gene and G1691A of factor V (FV Leiden) gene were studied by means of allele-specific polymerase chain reaction in 203 IE patients, 175 valvular heart disease (VHD) patients and 200 blood donors (BD). IE patients show higher cumulative frequencies of mutated alleles of PTH and FV Leiden [6.4 vs 3.25 %; OR 2.03 (95 % CI 0.97-3.66); p = 0.047] compared to BD, but not VHD. Device-related IE is enriched with FV Leiden, and prosthetic valve IE with PTH mutations (allele frequency 8.3 vs 2.2 % in native valve IE; p = 0.021). Vegetation size and embolic complications are not influenced by the examined thrombophilias. A trend for a higher mortality was observed in IE patients with any of the two thrombophilias studied. Our data do not support a role for factor V Leiden and G20210A prothrombin gene mutations in the susceptibility to IE. Whether any of these genetic polymorphisms play a role in a specific subtype of IE needs to be re-examined in larger studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25711313     DOI: 10.1007/s11739-015-1214-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  23 in total

Review 1.  Clinical practice. Infective endocarditis.

Authors:  Bruno Hoen; Xavier Duval
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

2.  The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation.

Authors:  M Margaglione; G D'Andrea; M d'Addedda; N Giuliani; G Cappucci; L Iannaccone; G Vecchione; E Grandone; V Brancaccio; G Di Minno
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

3.  New concepts in the pathophysiology of infective endocarditis.

Authors:  Eleonora Widmer; Yok-Ai Que; José M Entenza; Philippe Moreillon
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

4.  The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events.

Authors:  L I Kupferwasser; G Hafner; S Mohr-Kahaly; R Erbel; J Meyer; H Darius
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

5.  Factor V Leiden in patients with acute coronary syndromes.

Authors:  E Durante Mangoni; G J Davies; E G Tuddenham; G Ruggiero
Journal:  Ann Ital Med Int       Date:  1999 Jan-Mar

6.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

7.  Risk factors for "major" embolic events in hospitalized patients with infective endocarditis.

Authors:  Emanuele Durante Mangoni; Luigi E Adinolfi; Marie-Francoise Tripodi; Augusto Andreana; Michele Gambardella; Enrico Ragone; Davide F Precone; Riccardo Utili; Giuseppe Ruggiero
Journal:  Am Heart J       Date:  2003-08       Impact factor: 4.749

Review 8.  Update on infective endocarditis.

Authors:  Thomas M Bashore; Christopher Cabell; Vance Fowler
Journal:  Curr Probl Cardiol       Date:  2006-04       Impact factor: 5.200

Review 9.  Inflammation, endothelium, and coagulation in sepsis.

Authors:  Marcel Schouten; Willem Joost Wiersinga; Marcel Levi; Tom van der Poll
Journal:  J Leukoc Biol       Date:  2007-11-21       Impact factor: 4.962

10.  Hemostasis and inflammation: two of a kind?

Authors:  Peter Verhamme; Marc F Hoylaerts
Journal:  Thromb J       Date:  2009-11-18
View more
  4 in total

1.  Coagulation and infective endocarditis: sooner or later.

Authors:  Francesca Santilli; Paola Simeone; Giovanni Davì
Journal:  Intern Emerg Med       Date:  2015-06-02       Impact factor: 3.397

2.  Inherited Variation in Cytokine, Acute Phase Response, and Calcium Metabolism Genes Affects Susceptibility to Infective Endocarditis.

Authors:  Anastasia V Ponasenko; Anton G Kutikhin; Maria V Khutornaya; Natalia V Rutkovskaya; Natalia V Kondyukova; Yuri N Odarenko; Yana V Kazachek; Anna V Tsepokina; Leonid S Barbarash; Arseniy E Yuzhalin
Journal:  Mediators Inflamm       Date:  2017-06-04       Impact factor: 4.711

3.  Hypercoagulation detected by routine and global laboratory hemostasis assays in patients with infective endocarditis.

Authors:  Ekaterina M Koltsova; Maria A Sorokina; Alexandra S Pisaryuk; Nikita M Povalyaev; Anastasia A Ignatova; Dmitry M Polokhov; Elizaveta O Kotova; Alexander V Balatskiy; Fazoil I Ataullakhanov; Mikhail A Panteleev; Zhanna D Kobalava; Anna N Balandina
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

4.  Clinical significance of hyperhomocysteinemia in infective endocarditis: A case-control study.

Authors:  Domenico Iossa; Rosa Molaro; Roberto Andini; Antonio Parrella; Maria Paola Ursi; Irene Mattucci; Lucia De Vincentiis; Giovanni Dialetto; Riccardo Utili; Emanuele Durante-Mangoni
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.